Oragenics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
OGEN
Oragenics INCOragenics, Inc. reports continued operating losses and a going concern doubt, while advancing its lead mild traumatic brain injury drug candidate, ONP-002, into Phase 2a clinical trials in Q1 2026.
AMEX
OGEN
Oragenics INC10-K: Oragenics Reports 2024 Results, Focuses on Brain Injury Drug Development Amidst Financial Challenges
Oragenics reports a net loss for 2024 and focuses on developing its brain injury drug, ONP-002, while navigating financial uncertainties and litigation.
AMEX
OGEN
Oragenics INCOragenics, Inc.'s annual 10-K filing provides a comprehensive overview of its capital structure, including common and preferred stock details, and outlines the regulatory environment impacting its pharmaceutical development.